ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)

Trial Profile

ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Amantadine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Registrational; Therapeutic Use
  • Acronyms EASE LID 3
  • Sponsors Adamas Pharmaceuticals
  • Most Recent Events

    • 24 Aug 2017 According to an Adamas Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) has approved GOCOVRI (amantadine) extended release capsules for treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
    • 12 Aug 2017 Results published in the Movement Disorders.
    • 28 Apr 2017 Results of a pooled analysis from EASE LID and EASE LID 3 studies assessing the secondary outcome of ON time without troublesome dyskinesia and OFF time, presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top